GENALICE announced today it is partnering with deCODE Genetics to facilitate the large-scale testing of its unique DNA data processing software solution, GENALICE MAP. After a first successful round of evaluating GENALICE MAP on speed and quality, both parties agreed to extend the evaluation to include up to 10,000 full human genomes. Population wide analysis is crucial if the potential of whole genome sequencing for medical application in patients with complex diseases is to be realized. Data processing at that level represents a major challenge, however, GENALICE’s unique ability to process a full human genome on general purpose hardware in a matter of minutes makes population wide sequence variation analysis a reality.
deCODE Genetics has one of the world’s largest Biobanks and is generating large amounts of full human genome data with its Illumina HiSeq X Ten Next-Generation Sequencing (NGS) machines. GENALICE will install an XL version of its all-in-one bioinformatics appliance, GENALICE VAULT, which is preloaded with MAP, and can process one full human genome every other minute. deCODE’s Vice President of Informatics, Hakon Gudbjartsson, commented: “We had the opportunity to test GENALICE MAP on a XS version of their appliance and we were impressed with the results on speed and accuracy. We are pleased to move into a second phase, with the aim to stress test the software at population calling level and collaboration on further refinements”.
The project will kick off in August and final results are expected to be ready in December this year. Hans Karten, CEO/CTO of GENALICE, is delighted with the new partnership and stated: “deCODE’s unique dataset enables us to verify the quality of the output at population scale. GENALICE MAP is the only DNA data processing solution currently on the market that is capable of swiftly processing the huge quantities of data produced by the modern high volume sequencers with great accuracy but limited hardware requirements.
GENALICE is a highly innovative biomedical big data company, with global headquarters in the Netherlands. GENALICE designs and builds groundbreaking software solutions for ultra-fast, highly accurate and cost-effective DNA data processing and analysis on general purpose hardware. With GENALICE MAP, it has the first Next-Generation Sequencing (NGS) data processing pipeline with true population power. By partnering with world-renowned research institutes and healthcare companies, GENALICE is committed to unlocking the potential of whole genome and exome sequencing for biomarker discovery and medical application. More information on GENALICE can be found at www.genalice.com.
deCODE Genetics is a global leader in analyzing and understanding the human genome. Using its unique expertise and population resources, deCODE has discovered genetic risk factors for dozens of common diseases. The purpose of understanding the genetics of disease is to use that information to create new means of diagnosing, treating and preventing disease.